drugset / Trial / NCT03254199

A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps.

NCT03254199 ↗

Phase 2 Terminated 27 enrolled Flex Pharma, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The COMMIT Study will assess the safety and effectiveness of FLX-787 in men and women with Charcot-Marie-Tooth disease (CMT) experiencing muscle cramps. Participants will be asked to take two study products during the course of the study. One of these study products will be a placebo. Approximately 120 participants in 20 study centers across the United States are expected to take part. Participants will be in the study for approximately 3 months and visit the study clinic 3 times.

Timeline

Start
2017-10-16
Primary completion
2018-07-27
Completion
2018-07-27

Outcome

Outcome not reported

Stopped: “Sponsor”

Drugs

EvaluationDrugModalityDoseRoute
Subject FLX-787-ODT Unknown — —